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Mean HbA1c levels during follow-up for subjects with normal and elevated HbA1c level at baseline
Normal baseline HbA1c
(< 42 mmol/mol)
Elevated baseline HbA1c
( 42 mmol/mol)
Placebo Glucosamine Placebo Glucosamine
Baseline N (%) 150 (74%) 156 (76%) 43 (21%) 32 (16%)
HbA1c (mmol/mol) 36.7  2.9 37.1  2.8 50.6  11.1 51.6  16.8
1 year N (%) 124 (66%) 129 (63%) 36 (18%) 29 (14%)
HbA1c (mmol/mol) 37.2  2.8 37.8  3.0 48.1  9.9 48.9  12.9
2.5 years N (%) 131 (71%) 136 (66%) 34 (17%) 26 (13%)
HbA1c (mmol/mol) 37.3  2.8 37.8  3.7 48.6  12.5 50.2  11.8
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after 2.5 years. The glucosamine intervention had a non-signiﬁcant
effect on mean HbA1c level over 2.5 years, when analysed among all
subjects (p ¼ 0.94), and in subjects with a normal (p ¼ 0.60) or elevated
(p ¼ 0.82) HbA1c level at baseline (see table for stratiﬁed mean HbA1c
values over the follow-up period). However, compared to placebo,
subjects randomized to glucosamine sulphate had a signiﬁcantly
increased risk for attaining an elevated HbA1c level at follow-up (odds
ratio 2.81 [95% CI 1.12 - 7.04]).
Conclusions: A 2.5 year oral glucosamine sulphate intervention did not
affect mean HbA1c levels in overweight and obese women, but did lead
to signiﬁcant more womenwith increased levels of HbA1c ( 42 mmol/
mol). This HbA1c level is known to put people at ‘high risk for devel-
oping diabetes’. Long-term follow-up should demonstrate whether
these women will indeed develop diabetes at a higher rate and thus,
whether this should be considered as a true side effect of glucosamine
within this population.
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STRONTIUM RANELATE DECREASES THE NUMBER OF RAPID
RADIOLOGICAL PROGRESSORS FROM THE FIRST YEAR IN SEKOIA
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One of the most important issues in the studies of chondroprotection
is to be able to extrapolate a decrease in structural evolution into a
delay in knee surgeries such as joint replacement, as studies are
usually not long enough to provide this answer. Nevertheless, rapid
progressors on a short period of time (Group for the Respect of Ethics
and Excellence in Science (GREES) criteria) could help providing an
answer as these patients have been shown to be at higher risk of
surgeries.
Objective(s): The aim of this post hoc analysis is to describe the efﬁcacy
of Strontium Ranelate (SrRan) on rapid radiological progression, from
the ﬁrst year, in patients from SEKOIA study (randomised study with 3
years of treatment by 2 doses of SrRan versus placebo in knee
osteoarthritis).
Material and methods: 1683 patients suffering from symptomatic
primary knee osteoarthritis (Kellgren and Lawrence [KL] score of 2 or 3,
joint space width (JSW) of 2.5 to 5 mm and pain assessed on a visual
analogue scale of at least 40 mm) have been included and randomised
to receive SrRan 1 g/day, 2 g/day or placebo during 3 years. Knee X-rays
were performed yearly during 3 years, with a validated semi-automated
method of joint space narrowing (JSN) assessment. During the ﬁrst year,
radiological progressors (deﬁned as having a JSN  0,3 or  0,5 mm;
over the SDD), have been compared between groups using a Chi2 test in
the ITT population.
Results: ITT set included 1371 patients (82% of the randomized set;
445 patients in SrRan 1g group, 454 patients in SrRan 2g group and
472 patients in placebo group) with a mean age of 637 years, a mean
BMI of 305 kg/m2 and a mean JSW of 3.50.8 mm. 61% of patients
were KL II and 69% were female. A signiﬁcantly lower proportion of
patients in SrRan1g and 2g groups had radiological progression duringthe ﬁrst year compared to placebo: 12% and 13% versus 30%. The
estimate of the between groups difference E (SE) was -8.07 (2.42), 95%
CI [-12.81; -3.33] with p < 0.001 for SrRan 1g/d versus placebo and E
(SE) was -6.91 (2.45), 95% CI [-11.71; -2.10] with p ¼ 0.005 for SrRan
2g/d versus placebo. It corresponds to a decrease of the risk of rapid
progression by 40% and 35% in the SrRan 1g and 2g groups compared
to placebo
Conclusion: In patients suffering from primary knee OA, SrRan at the
dose of 1g or 2g/d decreases the number of rapid radiological pro-
gressors from the ﬁrst year of treatment suggesting that the beneﬁcial
structural effect could be clinically relevant.
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OLEUROPEIN OR RUTIN CONSUMPTION DECREASES THE
SPONTANEOUS DEVELOPMENT OF OA IN HARTLEY GUINEA PIG
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Purpose: Osteoarthritis is a high prevalence disease characterized by a
progressive loss of articular cartilage. Cartilage degradation is asso-
ciated with structural and metabolic changes in joint tissues such as
cartilage, subchondral bone and synovial membrane inﬂammation. One
reliable model to investigate the natural course of the disease and to
study the effects of treatments is Dunkin-Hartley guinea pigs devel-
oping spontaneous knee osteoarthritis which mimics the pathophy-
siological processes of human osteoarthritis. The potential protective
effects of three polyphenols found in olive oil (oleuropein) or fruits and
vegetables (rutin and curcumin) were assessed on this joint ageing and
osteoarthritis development model.
Methods: Sixty four-week old Dunkin-Hartley guinea pigs were random-
ized into four groups and received daily during 31 weeks either standard
guinea pig diet (control group) or a standard guinea pig diet enrichedwith
oleuropein (0.025 %), rutin (0.5%) or rutin/curcumin (0.5% / 0.25%) associ-
ation. Animals were weighed each week and blood samples taken every 6
weeksandat thetimeof euthanasia (week35).Biomarkersofosteoarthritis
(COLL2-1, COLL2-1NO2, Fib3-1, Fib3-2) as well as inﬂammation (PGE2)
were quantiﬁed in the serum. Histological assessments of knee cartilage
and synovial membrane were performed at week 35.
